Recombinant Plasminogen Activator Inhibitor-1 (PAI-1) for the Treatment or Prevention of Acute Lung Injury and Death in Severe Pulmonary Infection

Brief Description
This invention offers an innovative and effective therapeutic agent-recombinant plasminogen activator inhibitor-1 (rPAI-1)-for the treatment or prevention of acute lung injury and death in severe pulmonary infection of Streptococcus pneumoniae (S. pneumoniae).  The local application of rPAI-1 or small peptide sequence of this molecule into an infected patient?s airway would be a promising defense against the ravages of the disease.

S. pneumoniae is a major cause of morbidity and mortality worldwide.  Despite the widespread use of antibiotics, the mortality rate from severe S. pneumoniae pneumonia remains highest during the first 48 hours of hospitalization.  To date, there has been no effective therapeutic agent available to reduce acute lung injury and hemorrhage in the early stage of the disease that cause early death. Intratracheal application of rPAI-1 directly inhibits lung hemorrhages and injuries and thus reduces early death rate without inducing any release of bacterial hemolytic toxin, whereas antibiotics do not directly inhibit lung hemorrhage at all but still induce the release of bacterial toxin.  Small peptides derived from rPAI-1 as a therapeutic agent would be more suitable for pulmonary delivery for its low cost and low toxicity.
Patent Information:
Title Country Patent No. Issued Date
Methods for the Treatment or Prevention of Hemorrhagic Conditions United States 8,716,237 5/6/2014
For Information, Contact:
Matan Rapoport
Licensing Associate
University of Rochester
Jian-dong Li
Jae hyang Lim